Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple?

Danielle M. Andrade, Stephen W. Scherer, Berge A. Minassian

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In this work we analysed the characteristics of the cell-permeable peptide TAT-PTD fused to cystatin B (CSTB) to evaluate its potential for protein therapy of Unverricht-Lundborg (UL) epilepsy. TAT-PTD-CSTB does not penetrate the cells despite initial evidence of time and concentration-dependent transduction. Therefore, it cannot be used as a form of replacement of the intracytoplasmic protein missing in UL. Importantly, we discuss precautions to avoid false-positive results when working with TAT-PTD for protein therapy of neurological diseases.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalEpilepsy Research
Volume72
Issue number1
DOIs
StatePublished - Nov 1 2006

Fingerprint

Unverricht-Lundborg Syndrome
Cystatin B
Proteins
Epilepsy
Therapeutics
Peptides

Keywords

  • Blood-brain-barrier
  • Cell-permeable peptide
  • Progressive myoclonus epilepsy
  • Protein therapy
  • TAT-PTD
  • Unverrricht-Lundborg

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple? / Andrade, Danielle M.; Scherer, Stephen W.; Minassian, Berge A.

In: Epilepsy Research, Vol. 72, No. 1, 01.11.2006, p. 75-79.

Research output: Contribution to journalArticle

@article{f3c2b63b6ea6491b82ddb533879c1572,
title = "Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple?",
abstract = "In this work we analysed the characteristics of the cell-permeable peptide TAT-PTD fused to cystatin B (CSTB) to evaluate its potential for protein therapy of Unverricht-Lundborg (UL) epilepsy. TAT-PTD-CSTB does not penetrate the cells despite initial evidence of time and concentration-dependent transduction. Therefore, it cannot be used as a form of replacement of the intracytoplasmic protein missing in UL. Importantly, we discuss precautions to avoid false-positive results when working with TAT-PTD for protein therapy of neurological diseases.",
keywords = "Blood-brain-barrier, Cell-permeable peptide, Progressive myoclonus epilepsy, Protein therapy, TAT-PTD, Unverrricht-Lundborg",
author = "Andrade, {Danielle M.} and Scherer, {Stephen W.} and Minassian, {Berge A.}",
year = "2006",
month = "11",
day = "1",
doi = "10.1016/j.eplepsyres.2006.07.009",
language = "English (US)",
volume = "72",
pages = "75--79",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple?

AU - Andrade, Danielle M.

AU - Scherer, Stephen W.

AU - Minassian, Berge A.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - In this work we analysed the characteristics of the cell-permeable peptide TAT-PTD fused to cystatin B (CSTB) to evaluate its potential for protein therapy of Unverricht-Lundborg (UL) epilepsy. TAT-PTD-CSTB does not penetrate the cells despite initial evidence of time and concentration-dependent transduction. Therefore, it cannot be used as a form of replacement of the intracytoplasmic protein missing in UL. Importantly, we discuss precautions to avoid false-positive results when working with TAT-PTD for protein therapy of neurological diseases.

AB - In this work we analysed the characteristics of the cell-permeable peptide TAT-PTD fused to cystatin B (CSTB) to evaluate its potential for protein therapy of Unverricht-Lundborg (UL) epilepsy. TAT-PTD-CSTB does not penetrate the cells despite initial evidence of time and concentration-dependent transduction. Therefore, it cannot be used as a form of replacement of the intracytoplasmic protein missing in UL. Importantly, we discuss precautions to avoid false-positive results when working with TAT-PTD for protein therapy of neurological diseases.

KW - Blood-brain-barrier

KW - Cell-permeable peptide

KW - Progressive myoclonus epilepsy

KW - Protein therapy

KW - TAT-PTD

KW - Unverrricht-Lundborg

UR - http://www.scopus.com/inward/record.url?scp=33750361146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750361146&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2006.07.009

DO - 10.1016/j.eplepsyres.2006.07.009

M3 - Article

VL - 72

SP - 75

EP - 79

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -